
- August 2020
 - Volume 88
 - Issue 8
 
CE: Safely and Effectively Managing Excessive Daytime Sleepiness in Patients With Narcolepsy and Sleep Apnea
This activity is supported by an educational grant from Jazz Pharmaceuticals.
This activity is supported by an educational grant from Jazz Pharmaceuticals.
EDUCATIONAL OBJECTIVES
At the completion of this activity, the participant will be able to:
- Describe the incidence, etiology, and risk factors associated with excessive daytime sleepiness (EDS) in those with narcolepsy and obstructive sleep apnea (OSA)
 - Identify the recommended treatments for EDS associated with narcolepsy and OSA, including pharmacologic and nonpharmacologic options
 - Evaluate clinical safety and efficacy data for emerging therapies, including mechanisms of action and potential adverse effects
 - Explain the role of the pharmacist in identifying and treating EDS in those with narcolepsy and OSA
 
FACULTY
John M. Dopp, PharmD, MS
Associate Professor, School of Pharmacy
Clinical Pharmacist, Wisconsin Sleep Center
University of Wisconsin-Madison, Madison, Wisconsin
TARGET AUDIENCE: Community pharmacists
ACTIVITY TYPE: Application
RELEASE DATE: September 16, 2019
EXPIRATION DATE: September 16, 2020
ESTIMATED TIME TO COMPLETE ACTIVITY: 2.0 hours
FEE: This lesson is offered for free at 
Articles in this issue
about 5 years ago
Visual Impairment May Be Early Risk Factor for Dementiaabout 5 years ago
Help Patients Select Immune System Boostersabout 5 years ago
Understanding the Beers Criteria Is Essentialabout 5 years ago
Prepare for Anaphylaxis in School-Aged Childrenabout 5 years ago
Study: Apples, Berries, Tea May Protect Against Alzheimer Diseaseabout 5 years ago
Comprehensive and Targeted Reviews Are Essentialabout 5 years ago
Promoting Brain Function Is Key Amid COVID-19 Crisisabout 5 years ago
Recent Law Addresses the Opioid Crisisabout 5 years ago
Alexander Fleming Discovers PenicillinNewsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.














































































































































































































